Show source-provided references
6. Design, strategies, and therapeutics in nanoparticle-based siRNA delivery systems for breast cancer
10.1039/D3TB00278K ↗12. Dual-drug delivery by porous silicon nanoparticles for improved cellular uptake, sustained release, and combination therapy
10.1016/j.actbio.2015.01.021 ↗17. Nanobody-displaying porous silicon nanoparticles for the co-delivery of siRNA and doxorubicin
10.1039/D0BM01335H ↗18. The promising nanocarrier for doxorubicin and siRNA co-delivery by PDMAEMA-based amphiphilic nanomicelles
10.1021/acsami.5b11789 ↗20. Nonviral in vivo delivery of CRISPR-Cas9 using protein-agnostic, high-loading porous silicon and polymer nanoparticles
10.1021/acsnano.2c12261 ↗22. Effective delivery of siRNA into cancer cells and tumors using well-defined biodegradable cationic star polymers
10.1021/mp400049e ↗23. To PEGylate or not to PEGylate: Immunological properties of nanomedicine’s most popular component, polyethylene glycol and its alternatives
10.1016/j.addr.2021.114079 ↗24. Effects of polyethylene glycol on the surface of nanoparticles for targeted drug delivery
10.1039/D1NR02065J ↗26. Grafting of P (OEGA) onto magnetic nanoparticles using Cu (0) mediated polymerization: comparing grafting “from” and “to” approaches in the search for the optimal material design of nanoparticle MRI contrast agents
10.1021/ma401250f ↗28. Surface plasmons and visible light iniferter initiated polymerization for nanolocal functionalization of mesoporous separation layers
10.1002/adfm.202009732 ↗29. Comparison of visible and near-infrared wavelength-excitable fluorescent dyes for molecular imaging of cancer
10.1117/1.2717137 ↗32. Comprehensive review of mesoporous silica nanoparticles: drug loading, release, and applications as hemostatic agents
10.1002/slct.202400450 ↗33. Nanoparticle based medicines: approaches for evading and manipulating the mononuclear phagocyte system and potential for clinical translation
10.1039/D2BM00181K ↗